Advisory Board July 31, 2024
As demand for GLP-1 drugs like Ozempic and Wegovy continues to rise, some patients are turning to compounded versions of the drugs, which face fewer safety regulations. Now, there have been a growing number of reports of patients accidentally overdosing on these compounded drugs, leading to severe side effects.
5 catalysts that will impact the future of weight management drugs
Background
Semaglutide is a GLP-1 drug manufactured by Novo Nordisk. In 2017, FDA approved the drug to treat type 2 diabetes under the brand name Ozempic. A higher dose of the drug was later approved to treat obesity under the brand name Wegovy in 2021.
As demand increased, patients faced more difficulty accessing the drug, in part due to ongoing...
Today's Sponsors
Today's Sponsor